Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Nov 13;78(11):e70156. doi: 10.1002/iub.70156

ACOT11 Couples Lipid Hydrolysis to GPR40‐Associated Metabolic Rewiring and Neutrophil–PD‐L1‐Associated Immunomodulation in Non‐Small Cell Lung Cancer

Chutong Lin 1, Shanwu Ma 1, Yingze Ning 1, Huayu He 1, Jizheng Tang 1, Liang Jin 1, Wei He 1, Zhencheng Xiong 1, Guangliang Qiang 1,✉
PMCID: PMC13768821  PMID: 43031426

ABSTRACT

Chemoresistance in non‐small cell lung cancer (NSCLC) is frequently accompanied by metabolic reprogramming and immune evasion. ACOT11 (THEM1/STARD14) is an acyl‐CoA thioesterase that can tune intracellular free fatty acid (FFA) availability, but the downstream signaling and microenvironmental consequences relevant to resistance remain incompletely defined. ACOT11 expression and prognostic associations were analyzed in TCGA LUAD datasets (DESeq2) and Kaplan–Meier Plotter. ACOT11 levels were validated in paired patient tumor/adjacent tissues (n = 30) by RT–qPCR and immunohistochemistry. Gain‐ and loss‐of‐function studies were performed in A549 and NCI‐H1975 cells. FFAs were quantified colorimetrically/fluorometrically, while proliferation, clonogenicity, and motility were assessed using CCK‐8, colony formation, and Transwell assays. Bioenergetic profiling was performed by Seahorse OCR/ECAR measurements, complemented by ATP and lactate quantification. Neutrophils and CD8+ T cells were isolated from PBMCs for co‐culture assays with PD‐L1 blockade, and PD‐L1 was quantified by flow cytometry and immunoblotting. Tumor growth effects were evaluated in nude mouse xenografts with ACOT11 silencing and neutrophil supplementation. ACOT11 was dysregulated in LUAD and associated with worse survival, and was elevated in clinical tumors at mRNA and protein levels. In NSCLC cells, ACOT11 increased FFA abundance and selectively changes in GPR40 but not GPR120. Exogenous FFA partially rescued the proliferative and migratory defects induced by ACOT11 knockdown, and this rescue was blunted by GPR40 co‐silencing. ACOT11 depletion reduced OCR/ECAR, ATP, and lactate output, consistent with impaired energetic capacity, whereas FFA restored these parameters in a GPR40‐dependent manner, suggesting that this pathway likely contributes to the observed metabolic effects. ACOT11 aligned with neutrophil‐associated inflammatory signatures and increased MPO staining in tumors; ACOT11 loss reduced SPP1/CXCL2 expression, reversible by FFA–GPR40 signaling. Functionally, neutrophils were observed to restore PD‐L1 levels and suppress T‐cell effector outputs in co‐culture settings, and neutrophil supplementation partially rescued xenograft growth; PD‐L1 blockade enhanced T‐cell cytokine/perforin production and migration. Collectively, these findings support a working model in which ACOT11‐associated lipid signaling may contribute to an immunosuppressive milieu involving neutrophils and PD‐L1. ACOT11 is associated with increased FFA availability and engagement of a GPR40‐linked metabolic program, alongside neutrophil–PD‐L1‐associated immunosuppression, which may collectively contribute to NSCLC fitness. Targeting components of the ACOT11‐FFA‐GPR40 pathway, alone or combined with PD‐L1 blockade, may represent a mechanistically grounded strategy to weaken tumor bioenergetic reserve and immune escape in NSCLC.

Keywords: ACOT11 (THEM1/STARD14), free fatty acids (FFA), GPR40/FFAR1, metabolic reprogramming (OCR/ECAR), neutrophil–PD‐L1 immune evasion, non‐small cell lung cancer (NSCLC)

1. Introduction

Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, and treatment failure is frequently driven by intrinsic or acquired resistance to chemotherapy and targeted agents. In NSCLC, resistance phenotypes often co‐emerge with metabolic rewiring that supports survival under drug stress, including altered mitochondrial respiration, glycolytic flux, and bioenergetic reserve [1, 2]. These metabolic states are not only cell‐intrinsic but are also shaped by extracellular nutrient availability and signaling, particularly lipid‐derived cues in the tumor microenvironment [3].

A central biochemical node connecting lipid availability to tumor metabolism is the control of intracellular fatty acyl‐CoA pools and their hydrolysis into free fatty acids (FFAs) and CoA [4, 5]. The acyl‐CoA thioesterase (ACOT) enzyme family performs this hydrolysis, thereby tuning mitochondrial substrate supply, lipid signaling intermediates, and lipotoxic stress pathways [4, 5]. Within this family, acyl‐CoA thioesterase 11 (ACOT11; also known as THEM1/STARD14 in metabolic literature) has been mechanistically linked to the regulation of energy expenditure and oxygen consumption in vivo, consistent with a role in controlling the balance between fatty acid oxidation and storage [5]. Because ACOT11 activity can influence intracellular FFA availability, it is positioned to couple lipid metabolism to membrane receptor signaling pathways that sense FFAs [3, 6].

Clinical and functional evidence already suggests that ACOT11 is relevant to lung cancer biology [4]. In a translational lung cancer cohort and mechanistic cell‐line work, ACOT11 was reported to be upregulated in tumor tissue and to promote malignant phenotypes including proliferation, migration, invasion, and tumor growth in vivo, with poorer outcomes particularly noted in lung squamous carcinoma (LUSC). These observations support the idea that ACOT11 is not merely a metabolic housekeeping enzyme but can behave as an oncogenic facilitator in NSCLC contexts [4]. However, the specific link between ACOT11‐driven lipid remodeling, downstream FFA‐sensing pathways, and clinically relevant chemoresistance remains incompletely defined [4, 7].

FFA sensing is mediated in part by cell‐surface G‐protein‐coupled receptors (GPCRs), including receptors responsive to medium/long‐chain fatty acids such as FFAR1/GPR40 and FFAR4/GPR120 [3, 6]. Work defining GPR120 demonstrated that FFAs act as signaling molecules capable of triggering receptor‐mediated signal transduction rather than serving only as fuels. In cancer models, FFAR1/GPR40 signaling has been shown to engage oncogenic downstream pathways including Src and PI3K/AKT modules that control proliferation and survival, indicating that FFA–GPCR axes can be directly coupled to canonical pro‐growth circuitry. Because PI3K/AKT signaling is a well‐established determinant of drug resistance in NSCLC, FFA‐driven activation of this pathway represents a plausible biochemical bridge between lipid metabolism and chemoresistance [7, 8].

PI3K/AKT activation supports resistance phenotypes by promoting survival signaling, suppressing apoptosis, and enabling stress tolerance programs that blunt cytotoxic efficacy [1, 7, 9]. In NSCLC, experimental modulation of PI3K/AKT activity can shift sensitivity to cisplatin and targeted therapy, and pharmacologic PI3K inhibition can reverse resistance states driven by upstream activation. These data suggest that if ACOT11 increases the pool of bioactive FFAs and engages an FFA receptor linked to PI3K/AKT, then ACOT11 could plausibly strengthen chemoresistance through a metabolite‐to‐receptor‐to‐kinase signaling chain.

Beyond tumor‐cell autonomous signaling, lipid metabolism intersects with antitumor immunity, particularly through myeloid cell recruitment and checkpoint biology [10, 11]. Neutrophil trafficking into tumors is often organized by CXCR2 ligands such as CXCL1/2 that form gradients between bone marrow and tumor tissue, enabling sustained recruitment of tumor‐associated neutrophils (TANs) [10]. Importantly, TANs can suppress adaptive immunity through expression of PD‐L1, a mechanism demonstrated in human tumors and mouse models where PD‐L1+ neutrophils inhibit T‐cell proliferation and activation, and PD‐L1 blockade partially reverses this suppression [11]. Thus, metabolic pathways that influence chemokine production, neutrophil infiltration, or PD‐L1 checkpoint tone may contribute to therapy resistance through both cancer‐cell survival and immune evasion.

In this study, we integrate patient‐level expression and prognostic analyses with mechanistic experiments in NSCLC models to define an ACOT11‐centered association that links lipid hydrolysis, FFA signaling, PI3K/AKT activation, metabolic reprogramming, and neutrophil‐associated immunomodulation. By mapping how ACOT11 reshapes both tumor‐cell energetics and the immune microenvironment, we aim to clarify how dysregulated lipid handling can strengthen chemoresistance and identify actionable nodes within the pathway.

2. Experimental Procedures

2.1. Bioinformatic Analysis

RNA‐seq data from The Cancer Genome Atlas (TCGA) were used to identify differentially expressed genes (DEGs) between normal lung tissue and lung adenocarcinoma (LUAD) samples. Differential expression analysis was performed using the limma package. Genes with |log2 fold change| > 1 and p < 0.05 were defined as DEGs. Overall survival analysis was conducted using the Kaplan–Meier Plotter online platform (probe set 214763_at for ACOT11/STARD14), and survival curves were compared using the log‐rank test (https://kmplot.com/analysis/).

The TCGA–LUAD htseq FPKM data (https://xenabrowser.net/datapages/) was utilized to convert the TPM data, which included a total of 600 samples. After removing duplicate tissue samples, 58 control group samples and 524 cancer tissue samples were finally obtained. Visualization was performed using the ggplot2 and ggpubr packages of the R language and the analysis was conducted using the Wilcox test.

2.2. Human Tissue Samples

Paired primary tumor tissues (n = 30) and adjacent non‐tumor tissues (n = 30) were collected from Peking University Third Hospital. Written informed consent was obtained from all participants. The study was approved by the Peking University Third Hospital Medical Science Research Ethics Committee (2025‐472‐01). Tissue samples were processed for RNA extraction and/or immunohistochemistry as described below.

Inclusion criteria were patients who (1) were aged from 18 to 75 years; (2) had not received neoadjuvant therapy before surgery; (3) had no other malignant diseases. Exclusion criteria were patients who (1) had a previous history of radiotherapy or chemotherapy; (2) had other malignant diseases; (3) were not willing to participate in the study. Adjacent tissue refers to the tissue within a range of 2 cm from the edge of the primary tumor site, where no cancer cell invasion has been found under the microscope, and the background is relatively normal.

2.3. Cell Lines and Culture Conditions

Human lung cancer cell lines A549 and NCI‐H1975 were obtained from the American Type Culture Collection (ATCC, USA). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum, and antibiotics if used, and maintained at 37°C in a humidified incubator with 5% CO2. Cells were confirmed by STR identification and free from mycoplasma contamination.

2.4. Plasmids, siRNAs, and Transfection

For ACOT11 overexpression, pcDNA3.1‐ACOT11 (OE‐ACOT11) and the empty‐vector control (OE‐NC) were purchased from GenePharma (Shanghai, China). For knockdown experiments, 100 nM siRNAs targeting ACOT11 (si‐ACOT11) and a non‐targeting control siRNA (si‐NC) were obtained from the same vendor (si‐ACOT11 sense: GAGAGAUCACCAAGGUGAAdTdT; anti‐sense: UUCACCUUGGUGAUCUCUCdTdT). Cells were transfected using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's protocol. Cells were typically harvested 24–48 h post‐transfection for downstream assays.

2.5. Free Fatty Acid (FFA) Treatment

A mixed free fatty acid (FFA) supplement containing myristic acid (C14:0), palmitic acid (C16:0), and stearic acid (C18:0) (Sigma) was administered to cells at final concentrations of 1, 10, or 100 μM as indicated. Myristic acid, palmitic acid, and stearic acid were dissolved in DMSO and then combined with fatty acid‐free BSA (Sigma) to obtain approximately 0.5 mM of FFA‐BSA complex.

2.6. Western Blotting

Total protein was extracted from cultured cells or human tissues using RIPA lysis buffer (Beyotime. China) Protein concentration was determined using BCA assay (Beyotime, China). Equal amounts of protein were separated by 10% SDS–PAGE and transferred onto PVDF membranes (Beyotime, Shanghai, China). Membranes were blocked with 5% BSA (Solarbio, China) for 2 h., incubated with primary antibodies at 4°C for 24 h, and then incubated with secondary antibodies (ab7090, 1:1000) for 2 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence kit (Thermo Fisher Scientific, USA). Band intensities were quantified by densitometry and normalized to GAPDH.

Primary antibodies used were: ACOT11 (10776–1‐AP, 1:5000, Proteintech), GPR40 (NBP1‐00860, 1:2000, Novus), GPR120 (ab263964, 1:1000, Abcam), PD‐L1 (orb1239835, 1:1000, Biorbyt), AKT (10176‐2‐AP, 1:2000, Proteintech), p‐AKT (Ser473) (66444‐1‐Ig, 1:2000, Proteintech) and GAPDH (ab8245, 1:1000, Abcam). The relative protein expression levels of ACOT11, GPR40, GPR120, PD‐L1, and total AKT were normalized to GAPDH. The relative protein expression level of p‐AKT was quantified relative to total AKT, normalized to GAPDH, and expressed as fold change over control. Phosphorylation of PI3K was not directly assessed in this study. PI3K involvement in the proposed pathway is inferred from the observed changes in AKT phosphorylation (p‐AKT Ser473) and from published evidence in other tumor systems.

2.7. RNA Extraction and RT–qPCR

Total RNA was isolated from cells using TRIzol reagent (Thermo Fisher Scientific, USA). cDNA was synthesized using PrimeScript RT Reagent Kit (Takara, China). Quantitative PCR was performed with a SYBR Green PCR kit (Toyobo, Japan) on ABI 7900 instrument. The reverse transcription reaction system and conditions were performed according to the manufacturer's instructions for the PrimeScript RT Reagent Kit. The reaction mixture consisted of 1 μg of total RNA, 4 μL of Mix, 1 μL of dsDNase, and nuclease‐free water was added to a final volume of 20 μL. The thermal cycling conditions were as follows: 37°C for 2 min, 55°C for 15 min, and 85°C for 5 min. Quantitative real‐time PCR was conducted to examine the mRNA expression levels in tissues and cells, following the protocol provided with the SYBR Green PCR Kit. Each 20‐μL reaction contained 2 μL of cDNA sample, 10 μL of TB Green Premix Ex Taq II, 1 μL each of forward and reverse primers (10 μM), and 6 μL of DEPC‐treated water. The amplification program consisted of an initial denaturation at 95°C for 3 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 20 s, and extension at 72°C for 30 s. Relative mRNA expression was calculated using the 2−ΔΔCt method and normalized to the expression of housekeeping gene (GAPDH) as the internal control. To confirm GAPDH stability under our experimental conditions, we followed the geNorm algorithm as previously described [12]. According to this algorithm, GAPDH exhibited an M value below the accepted threshold of 0.5, indicating high expression stability. Primer specificity was verified by melt curve analysis, which generated a single peak for each primer pair. Primer sequences included:

ACOT11: Forward 5′‐TGACAAGTTCCTCTCCTTCCACATG‐3′; Reverse 5′‐TGGCGTCGTCCTCGTCTACC‐3′. PDCD1: Forward 5′‐CTACGACCCTGGAGCTCCT‐3′; Reverse 5′‐(CTGCTCGTGGTGACCGAAG)‐3′. SPP1 Forward 5′‐CGAGGTGATAGTGTGGTTTATGG‐3′; Reverse 5′‐GCACCATTCAACTCCTCGCTTTC‐3′; and CXCL2 Forward 5′‐GAAAGCTTGTCTCAACCCCG‐3′; Reverse 5′‐AAGATACTGAACAAAGGCAAGG‐3′; GPR40 Forward 5′‐TCTCCTTCGGCCTCTATGTGG‐3′; Reverse 5′‐ACCAGGCTAGGGGTGAGAC‐3′; GPR120 Forward 5′‐TGCTCCTGCTGCTGTTCCT‐3′; Reverse 5′‐CGGTGAGATAGATGGTGGTGAA‐3′; GAPDH Forward 5′‐TGACATCAAGAAGGTGGTGAAGCAG‐3′; Reverse 5′‐GTGTCGCTGTTGAAGTCAGAGGAG‐3′.

2.8. Cell Viability Assay (CCK‐8)

A549 and NCI‐H1975 cells were seeded into 96‐well plates at (3–5 × 103 cells/well) and allowed to adhere overnight. Cells were then transfected with si‐NC or si‐ACOT11 as described above. Cells were treated with a mixed FFA supplement (myristic acid, palmitic acid, and stearic acid) at the indicated concentrations (1, 10, or 100 μM) for 24 h. Cell viability was measured using the Cell Counting Kit‐8 (CCK‐8; Dojindo, Japan) by adding 10 μL CCK‐8 reagent to each well and incubating for 2 h at 37°C. Absorbance was recorded at 450 nm using a microplate reader (Thermo Fisher Scientific, USA). Viability was calculated relative to the si‐NC control group. All experiments were conducted independently at least three times.

2.9. Colony Formation Assay

Cells were seeded into 6‐well plates at (1 × 103 cells/well) and cultured for 14 days. Colonies were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Colonies containing ≥ 50 cells were counted. Cells were cultured for 2 weeks and the medium was changed every 3 days.

2.10. Transwell Invasion/Migration Assay

Transwell chambers (8 μm pore size; Corning, USA) were used. For invasion assays, the upper chamber was coated with Matrigel (BD Biosciences, USA). Cells in serum‐free medium were seeded into the upper chamber at (5 × 104 cells), and medium containing 20% FBS was added to the lower chamber as a chemoattractant. After 48 h, cells on the upper surface were removed, and invaded cells on the lower surface were fixed (4% paraformaldehyde) and stained (0.1% crystal violet). Cells were imaged using an Olympus microscope, and invaded cells were quantified in three random fields per membrane.

2.11. Free Fatty Acid Quantification

A total of 1 × 105 cells were seeded in 10‐cm dishes in 8 mL medium. After 48 h, culture medium and cells were collected. Extracellular and intracellular FFAs were quantified using a Free Fatty Acid Quantification Colorimetric/Fluorometric Kit (BioVision, USA) according to the manufacturer's instructions. The results were detected on a microplate reader at excitation/emission = 485/590 nm (Eplex, Tecan) and calculated the concentration.

2.12. ATP And Lactate Measurements

Cells were seeded at equal density in 6‐well plates. After treatment, cells were trypsinized and resuspended as single‐cell suspensions. An aliquot of the cell suspension was mixed with trypan blue, and viable cells (trypan blue‐excluding) were counted using an automated cell counter. Based on the cell count, the volume of buffer was adjusted so that the resulting lysates from all groups were normalized to equal numbers of viable cells (1 × 105 cells). Cells were collected and centrifuged (5 min, 12,000 rpm), and supernatants were used for metabolite measurements. ATP levels were measured using an ATP assay kit (Solarbio, China), and lactate levels were measured using a Lactate Assay Kit (Jiancheng, China) following the manufacturers' protocols. For ATP extraction, cells were lysed in 100 μL ATP determination buffer prior to quantification.

2.13. Elisa

Chemokines and cytokines produced in co‐culture systems were quantified using commercial ELISA kits, for example, TNF‐α, IFN‐γ, (EK182, EK180, MultiSciences, China), perforin (ab46068, Abcam, China) according to the manufacturer's instructions.

2.14. Isolation of PBMCs, Neutrophils, and CD8 + T Cells

Peripheral blood from healthy donors was collected under an approved protocol. PBMCs were isolated by density‐gradient centrifugation using Ficoll‐Paque Plus. Neutrophils were harvested after red blood cell lysis using a lysis solution. CD66b+ neutrophils and CD8+ T cells were purified using magnetic separation with anti‐CD66b and anti‐CD8 MicroBeads (Miltenyi Biotec). Prior to use in any experiment, purity (> 95%) and viability (> 95%) were confirmed by flow cytometry and Trypan blue exclusion, respectively.

2.15. Neutrophil–CD8 + T Cell Co‐Culture and PD‐L1 Blockade

Purified CD8+ T cells (1 × 105 cells/well, 96‐well plates) were co‐cultured with A549‐ or NCI‐H1975‐“induced” neutrophils in RPMI‐1640 supplemented anti‐CD3/CD28 stimulation. Neutrophils and CD8+ T cells were co‐cultured at a 2:1 ratio in 200 μL medium with or without a human anti‐PD‐L1 neutralizing antibody (4 μg/mL; Abcam). Where indicated, Transwell co‐cultures were performed using 0.4 μm pore inserts (Corning). After 3 days, cells and/or supernatants were collected for downstream analyses. A549‐ or NCI‐H1975‐“induced” neutrophils were obtained by culturing in tumor cells‐conditioned medium for 24 h.

2.16. Flow Cytometry

Single‐cell suspensions were prepared for PD‐L1 analysis. Tumor tissues were minced and enzymatically digested using 1 mg/mL collagenase/0.1 mg/mL DNase for 45 min. Red blood cells were lysed using ACK lysis buffer. Cells were filtered through 40–70 μm strainers and resuspended in FACS buffer (PBS + 2% FBS). Cells were stained with fluorochrome‐conjugated antibodies for 30 min at 4°C protected from light, washed twice, and analyzed on a flow cytometer (BD Biosciences, USA) using FlowJo software (version 10). For PD‐L1 surface staining, anti‐human PD‐L1 antibody (clone 29E.2A3, BioLegend, #329708) was used.

Gating strategies were applied based on forward scatter (FSC), side scatter (SSC), viability dye exclusion, and specific marker (% CD11b + Ly6G+ neutrophils). Mean Fluorescence Intensity (MFI) of PD‐L1 was measured.

2.17. Seahorse Analysis of ECAR and OCR

ECAR and OCR were measured using a Seahorse XFe96 Extracellular Flux Analyzer (Agilent Seahorse Bioscience, USA). Cells were seeded at 1 × 104 cells/well in Seahorse microplates and equilibrated in Seahorse XF base medium prior to measurements. For ECAR (glycolysis stress test), glucose (10 mM), oligomycin (1 μM), and 2‐deoxyglucose (2‐DG; 50 mM) were injected sequentially, and data were analyzed using the Glycolysis Stress Test Report Generator. For OCR (mitochondrial stress test), XF base medium supplemented with glucose (10 mM), pyruvate (1 mM), and glutamine (2 mM) was used, followed by sequential injection of oligomycin (1.5 μM), FCCP (1 μM), and rotenone/antimycin A (0.5 μM). Data were analyzed using the Cell Mito Stress Test Report Generator. To eliminate the influence of inter‐well discrepancies in cell density on metabolic measurements, total cellular protein was extracted using RIPA lysis buffer after the Seahorse assay and quantified via the BCA method (Beyotime). OCR and ECAR raw values were then normalized against the total protein concentration of each individual well, and the resultant data are reported as pmol min−1 μg−1 protein and mpH min−1 μg−1 protein, respectively.

2.18. Xenograft Tumor Model and Neutrophil Supplementation

All animal procedures were approved by the Peking University Third Hospital Experimental Animal Ethics Committee (2025‐115‐02). SCID/NOD mice (n = 20; Vital River, Beijing, China) were used at (6 weeks, 18–20 g). A549 cells transfected as indicated were injected subcutaneously into the right flank (2 × 105 cells, 0.2 mL). Tumor volumes were measured at 7 days using calipers and calculated as length × width2/2. 14 days after injection, human purified neutrophils were administered (i.v.) (5 × 106 cells, 100 μL) once a week. At Day 28, mice were euthanized by cervical dislocation under anesthesia (Inhalation of CO2), and tumors were excised, weighed, and processed for downstream assays.

2.19. Immunohistochemistry (IHC)

Paraffin‐embedded tumor tissues were sectioned at 4 μm, deparaffinized, and rehydrated. After antigen retrieval (Citrate buffer solution with pH 6.0) and blocking with 3% hydrogen peroxide, sections were incubated with primary antibodies against ACOT11 (HPA041047, 1:200) and MPO (SAB56000306, 1:200) overnight (12 h) at 4°C. Sections were then incubated with appropriate secondary antibodies (ab6721, 1:1000, Abcam) for 2 h at room temperature. Signal was developed with DAB and counterstained with hematoxylin. Images were acquired using a Nikon microscope. Quantification of positive cells was performed using ImageJ.

2.20. Statistical Analysis

All statistical analyses were performed using GraphPad Prism 9. Continuous data following a normal distribution are presented as the mean ± standard deviation (SD), whereas those with a non‐normal distribution are reported as the median with interquartile range (IQR). Between‐group comparisons were performed using the Student's t‐test for normally distributed data and the Wilcoxon rank‐sum test for non‐normally distributed data. For comparisons involving three or more groups, one‐way ANOVA was employed for normally distributed data, and the Kruskal–Wallis test was used as its nonparametric counterpart. When ANOVA reached statistical significance, Tukey's HSD test was applied for post hoc pairwise comparisons with p‐values adjusted by the Tukey method. For experiments containing both treatment and time variables—including Seahorse metabolic time‐course profiles and longitudinal tumor growth curves—two‐way repeated measures ANOVA with Tukey's HSD post hoc test was used to evaluate the main effects and their interaction. All experiments were conducted independently at least three times. A threshold of p < 0.05 with two‐sided statistical tests was considered statistically significant. For intergroup comparisons: *p < 0.05, **p < 0.01, ***p < 0.001 (Group 1 vs. Group 2); # p < 0.05, ## p < 0.01, ### p < 0.001 (Group 2 vs. Group 3); & p < 0.05, && p < 0.01, &&& p < 0.001 (Group 3 vs. Group 4).

3. Results

3.1. ACOT11 is Dysregulated in Human Tumors and Functionally Contributes to In Vivo Tumor Growth

To define whether ACOT11 is altered in cancer, we first interrogated public transcriptomic data from lung LUAD and matched normal controls. ACOT11 mRNA levels differed significantly between control lung and LUAD in both unpaired and paired comparisons, indicating robust tumor‐associated deregulation across cohorts (Figure 1a). In parallel, survival stratification analysis revealed that high expression of the STARD14 probe set (214763_at) was associated with reduced overall survival, supporting the clinical relevance of lipid‐handling gene programs in patient outcome (Figure 1b). We next validated ACOT11 expression in an independent set of human specimens. Quantitative RT–PCR demonstrated a significant difference in ACOT11 transcript abundance between tumor tissue and normal controls (p = 0.0001), confirming tumor‐associated modulation of ACOT11 at the mRNA level in clinical samples (Figure 1c). Consistent with these findings, immunohistochemistry showed stronger ACOT11 immunoreactivity in tumor sections relative to normal tissue, indicating that deregulation is also evident at the protein level (Figure 1d). Finally, to test whether ACOT11 is functionally linked to malignant growth, we performed in vivo xenograft assays following ACOT11 silencing. Compared with control (si‐NC), ACOT11 knockdown (si‐ACOT11) reduced tumor burden, reflected by smaller excised tumors and a marked suppression of tumor volume accumulation over time, culminating in significantly lower terminal tumor weight (Figure 1e). Together, these data connect tumor‐associated deregulation of ACOT11 with measurable effects on tumor progression in vivo (Figure 1a–e).

FIGURE 1.

FIGURE 1

ACOT11 deregulation in tumors and contribution to tumor growth in vivo. (a) ACOT11 mRNA expression in LUAD and non‐tumor controls from a public dataset shown as unpaired (left) and paired (right) comparisons; p values indicate Wilcoxon tests, n = 524 tumor samples, n = 58 normal samples. (b) Kaplan–Meier overall survival analysis stratified by STARD14 (probe 214763_at) expression (high vs. low); hazard ratio (HR) and log‐rank p value are indicated on the plot, n = 524 tumor samples. (c) qRT–PCR quantification of ACOT11 mRNA in human tumor samples versus normal tissue; each point represents one sample; p value was determined by paired Student's t‐test, n = 30 paired samples. (d) Representative immunohistochemistry images showing ACOT11 staining in normal and tumor tissues. (e) Xenograft growth following ACOT11 silencing (si‐ACOT11) versus control (si‐NC): Representative excised tumors (left), tumor growth curve (middle), and endpoint tumor weight (right). Tumor growth curves were analyzed by two‐way repeated measures ANOVA with Tukey's HSD post hoc test; endpoint tumor weight was analyzed by unpaired Student's t‐test, n = 5 mice per group. Data are presented as mean ± SD.

3.2. ACOT11 Modulates Cellular Lipid Handling and Selectively Regulates GPR40 Expression in LUAD Cells

To establish experimental control over ACOT11 in LUAD models, we then validated gain‐ and loss‐of‐function conditions in A549 and NCI‐H1975 cells. ACOT11 overexpression (OE‐ACOT11) markedly increased ACOT11 protein abundance relative to the negative control (OE‐NC), as confirmed by immunoblotting and densitometric quantification normalized to GAPDH (Figure 2a). Conversely, siRNA‐mediated depletion efficiently reduced ACOT11 protein levels compared with the non‐targeting siRNA control (si‐NC) in both cell lines (Figure 2b). Given ACOT11's role in lipid metabolism, we next assessed whether altering ACOT11 impacts cellular free fatty acid (FFA) levels. ACOT11 overexpression was associated with an upward shift in FFA content in both A549 and NCI‐H1975 cells (Figure 2c), whereas ACOT11 knockdown showed a reciprocal trend toward reduced FFA levels relative to si‐NC (Figure 2c). Because FFAs can signal through fatty‐acid–responsive GPCRs, and GPR40 (FFAR1) and GPR120 (FFAR4) are the principal G protein‐coupled receptors (GPCRs) for long‐chain free fatty acids (LCFAs) and are the most functionally well‐characterized in metabolic regulation [13, 14], we first assessed the necessity of these two receptors. In A549 cells, OE‐ACOT11 was accompanied by higher GPR40 protein levels, while ACOT11 silencing was associated with lower GPR40 compared with si‐NC; in contrast, GPR120 levels remained largely unchanged across conditions (Figure 2d). The same pattern was reproduced in NCI‐H1975 cells, where ACOT11 overexpression robustly elevated GPR40 and ACOT11 knockdown reduced it, again without an overt effect on GPR120 (Figure 2e). After knockdown or overexpression of ACOT11, the mRNA expression levels of GPR40 (FFAR1) and GPR120 (FFAR4) were examined. Compared with the control group, no significant changes were observed in either gene under both conditions (Figure 2f), indicating that the observed changes in GPR40 protein abundance were not accompanied by corresponding transcriptional alterations. In rescue experiments, knockdown of ACOT11 led to a reduction in GPR40 protein levels, which were partially restored upon supplementation with free fatty acids (FFAs) (Figure 2g). These findings indicate that ACOT11‐associated effects in lung cancer are accompanied by changes in GPR40 protein expression, suggesting a potential link between these events. Furthermore, knockdown of ACOT11 significantly downregulated the phosphorylation of AKT at Ser473 (p‐AKT Ser473), whereas ACOT11 overexpression markedly increased p‐AKT Ser473 levels. Notably, FFA supplementation partially rescued the decrease in p‐AKT Ser473 induced by ACOT11 knockdown (Figure 2h). In addition, knockdown of GPR40 resulted in a pronounced reduction in p‐AKT Ser473 levels (Figure 2i), suggesting that AKT signaling may participate in the downstream effects of ACOT11‐associated signaling (consistent with engagement of the PI3K/AKT pathway). Collectively, these data indicate that ACOT11‐driven lipid alterations are associated with the selective upregulation of the FFA receptor GPR40 (Figure 2a–i).

FIGURE 2.

FIGURE 2

Validation of ACOT11 manipulation and its association with FFA levels and selective regulation of GPR40. (a) Western blot analysis of ACOT11 in A549 and NCI‐H1975 cells transfected with negative control (OE‐NC) or ACOT11 overexpression construct (OE‐ACOT11). Right, densitometric quantification of ACOT11 protein levels normalized to GAPDH. (b) Western blot validation of ACOT11 knockdown in A549 and NCI‐H1975 cells transfected with control siRNA (si‐NC) or ACOT11‐targeting siRNA (si‐ACOT11). Right, densitometric quantification normalized to GAPDH. (c) Cellular free fatty acid (FFA) levels (nmol) in A549 and NCI‐H1975 following ACOT11 overexpression (left) or ACOT11 knockdown (right). (d) Immunoblotting of GPR40 and GPR120 in A549 cells under OE‐NC, OE‐ACOT11, si‐NC, or si‐ACOT11 conditions. Right, quantification of GPR40 and GPR120 protein levels normalized to GAPDH. (e) Immunoblotting of GPR40 and GPR120 in NCI‐H1975 cells under OE‐NC, OE‐ACOT11, si‐NC, or si‐ACOT11 conditions. Right, quantification of GPR40 and GPR120 protein levels normalized to GAPDH. (f) The mRNA expression levels of GPR40 (FFAR1) and GPR120 (FFAR4) after knockdown or overexpression of ACOT11. (g) FFA supplementation partially restores GPR40 protein expression following ACOT11 knockdown. (h) ACOT11 knockdown suppresses AKT phosphorylation at Ser473, which is partially restored by FFA supplementation, whereas ACOT11 overexpression enhances p‐AKT Ser473 levels. (i) Knockdown of GPR40 suppresses AKT phosphorylation at Ser473. (a–i) All bar graph data are presented as mean ± SD from n = 3 independent experiments. Comparisons between two groups were performed using unpaired Student's t‐test; comparisons among three or more groups were performed using one‐way ANOVA with Tukey's HSD post hoc test.

3.3. Exogenous Fatty Acids Rescue the Growth and Motility Defects Caused by ACOT11 Depletion With GPR40 Contributing to This Effect

To test whether the functional consequences of ACOT11 loss are linked to altered fatty‐acid availability, we supplemented ACOT11‐silenced LUAD cells with exogenous FFA. ACOT11 knockdown significantly reduced cell viability in both A549 and NCI‐H1975 cells compared with the siRNA negative control (si‐NC), and FFA supplementation partially restored viability in a dose‐dependent manner, with the strongest rescue observed at intermediate FFA concentrations (Figure 3a). We next asked whether ACOT11 depletion impairs clonogenic growth. In colony formation assays, si‐ACOT11 markedly decreased the number of colonies relative to si‐NC in both cell lines, indicating reduced long‐term proliferative capacity (Figure 3b). Addition of FFA restored colony‐forming ability in ACOT11‐silenced cells, consistent with lipid availability acting downstream of ACOT11. Importantly, co‐silencing of GPR40 blunted the FFA‐mediated rescue, reducing colony numbers toward the si‐ACOT11 condition, supporting a requirement for GPR40 signaling in this compensatory effect (Figure 3b). Because lipid‐driven GPCR pathways can also regulate cell movement, we evaluated cell motility using Transwell assays. ACOT11 knockdown substantially reduced the number of Transwell‐positive cells compared with si‐NC, while FFA supplementation restored migratory activity (Figure 3c). As observed for clonogenic growth, the FFA‐induced recovery was diminished when GPR40 was simultaneously silenced, indicating that the pro‐migratory effect of FFA in the setting of ACOT11 loss is mediated, at least in part, through GPR40 (Figure 3c). Together, these findings functionally link ACOT11‐dependent lipid handling to LUAD cell growth and motility with GPR40 appearing to play a contributory role in this process (Figure 3a–c).

FIGURE 3.

FIGURE 3

Free fatty acids partially reverse the anti‐proliferative and anti‐migratory effects of ACOT11 knockdown via GPR40. (a) Cell viability in A549 and NCI‐H1975 cells transfected with si‐NC or si‐ACOT11, with rescue conditions including graded concentrations of free fatty acids (FFA). (b) Representative colony formation images (left) and quantification (right) in A549 and NCI‐H1975 cells under si‐NC, si‐ACOT11, si‐ACOT11 + FFA, and si‐ACOT11 + FFA + si‐GPR40 conditions. (c) Representative Transwell images (left) and quantification (right) under the same conditions as in (b), showing reduced motility upon ACOT11 depletion, rescue by FFA supplementation, and attenuation of rescue with GPR40 co‐silencing. Data are presented as mean ± SD from n = 3 independent experiments. All multi‐group comparisons were analyzed by one‐way ANOVA with Tukey's HSD post hoc test for multiple comparisons.

3.4. ACOT11 Supports a Glycolytic–Energetic Program and is Associated With Neutrophil‐Related Inflammatory Signatures That are Correlate With FFA–GPR40 Signaling

To determine whether ACOT11 influences metabolic state, we profiled mitochondrial respiration and glycolytic flux after ACOT11 silencing, with or without FFA supplementation and GPR40 co‐silencing. In A549 cells, ACOT11 knockdown reduced the oxygen consumption rate (OCR) across the assay, including the stimulated phases, consistent with impaired oxidative metabolism, whereas FFA supplementation partially restored OCR; this rescue was attenuated when GPR40 was simultaneously silenced (Figure 4a). In the same cells, extracellular acidification rate (ECAR) was also suppressed by ACOT11 depletion and was partially recovered by FFA in a GPR40‐dependent manner, indicating that ACOT11 loss compromises glycolytic output as well (Figure 4b). A comparable pattern was observed in NCI‐H1975 cells, where si‐ACOT11 reduced OCR and ECAR, FFA supplementation restored both parameters, and the rescue was blunted by GPR40 co‐silencing (Figure 4c,d). Consistent with the flux measurements, functional metabolic readouts showed that ACOT11 depletion decreased lactate production and cellular ATP levels in both LUAD cell lines, while FFA supplementation partially rescued these outputs; again, co‐silencing GPR40 reduced the magnitude of this rescue (Figure 4e,f). These findings support a model in which ACOT11 maintains cellular energetic capacity with FFA‐GPR40 signaling potentially contributing to this process (Figure 4a–f).

FIGURE 4.

FIGURE 4

ACOT11 sustains metabolic output and inflammatory gene expression via an FFA–GPR40 association and aligns with neutrophil‐associated signatures. (a) Seahorse OCR time‐course in A549 cells under si‐NC, si‐ACOT11, si‐ACOT11 + FFA, and si‐ACOT11 + FFA + si‐GPR40 conditions. (b) Seahorse ECAR time‐course in A549 cells under the same conditions as in (a). (c) Seahorse OCR time‐course in NCI‐H1975 cells under si‐NC, si‐ACOT11, si‐ACOT11 + FFA, and si‐ACOT11 + FFA + si‐GPR40 conditions. (d) Seahorse ECAR time‐course in NCI‐H1975 cells under the same conditions as in (c). Seahorse OCR/ECAR time‐course data (a–f) are presented as mean ± SD and were analyzed by two‐way repeated measures ANOVA with Tukey's HSD post hoc test (n = 3 independent experiments). (e) Lactate production (μM/10^6 cells) in A549 and NCI‐H1975 under the indicated conditions. (f) ATP levels (μM/106 cells) in A549 and NCI‐H1975 under the indicated conditions. Bar graphs (e, f) were analyzed by one‐way ANOVA with Tukey's HSD post hoc test (n = 3 independent experiments) and data are presented as mean ± SD. (g) Correlation plots showing ACOT11 expression versus estimated tumor purity and neutrophil infiltration in LUAD. Correlation between ACOT11 expression and tumor purity/neutrophil infiltration was assessed by Spearman's rank correlation test; each point represents an individual TCGA sample (n = 524 tumor samples). (h) Representative immunohistochemistry images of MPO in normal and tumor tissues. (i) qRT–PCR analysis of SPP1 and CXCL2 mRNA expression in A549 and NCI‐H1975 cells under si‐NC, si‐ACOT11, si‐ACOT11 + FFA, and si‐ACOT11 + FFA + si‐GPR40 conditions. (j) Representative Transwell migration images under the indicated conditions. (k) Quantification of migrated cells corresponding to (j). qRT–PCR (i) and Transwell migration data (j) were analyzed by one‐way ANOVA with Tukey's HSD post hoc test (n = 3 independent experiments).

Because metabolic rewiring in tumors can couple to inflammatory programs, we next examined associations between ACOT11 expression and immune‐related features in LUAD. ACOT11 expression showed a measurable relationship with estimated neutrophil infiltration, whereas the association with tumor purity was weak (Figure 4g). In line with a neutrophil‐linked phenotype, myeloperoxidase (MPO) immunostaining was higher in tumor tissue compared with normal tissue (Figure 4h). Finally, we tested whether ACOT11 perturbation affects inflammatory mediators in tumor cells. ACOT11 knockdown reduced the mRNA expression of SPP1 and CXCL2 in both A549 and NCI‐H1975 cells, and FFA supplementation partially restored their expression; this effect was diminished by GPR40 co‐silencing (Figure 4i). Functionally, in Transwell assays, FFA supplementation partially rescued the reduced migratory phenotype caused by ACOT11 knockdown, while GPR40 co‐silencing again weakened the rescue (Figure 4j,k). Together, these data connect ACOT11‐driven lipid signaling to maintenance of glycolytic/energetic output and to a tumor‐cell program that aligns with neutrophil‐associated inflammatory features, with FFA‐GPR40 appearing to contribute to these processes (Figure 4a–k).

3.5. ACOT11 Constrains T‐Cell Effector Function and Supports Tumor Growth in Association With PD‐L1 Expression and Neutrophil‐Related Features

To investigate whether ACOT11 influences immune checkpoint signaling, we quantified PD‐L1 on LUAD cells following ACOT11 silencing. Flow‐cytometric analysis showed a marked reduction in PD‐L1 signal intensity in si‐ACOT11 cells compared with si‐NC controls, whereas exposure to neutrophils partially restored PD‐L1 levels (Figure 5a). Consistent with tumor–myeloid crosstalk, neutrophils conditioned by LUAD cells exhibited increased PD‐L1 protein relative to neutrophils alone, as assessed by immunoblotting (Figure 5b). We next tested whether disrupting PD‐L1 signaling modulates T‐cell effector outputs in a neutrophil‐containing context. In co‐culture assays, PD‐L1 blockade increased the production of key cytotoxic/Th1‐associated mediators—including TNF‐α, IFN‐γ, and perforin—relative to IgG controls in the presence of A549‐conditioned neutrophils (Figure 5c) and NCI‐H1975‐conditioned neutrophils (Figure 5d). Functionally, PD‐L1 blockade also enhanced T‐cell migration in Transwell assays for both LUAD models, indicating improved immune cell trafficking when PD‐L1 signaling is inhibited (Figure 5e). In parallel, PDCD1 (PD‐1) mRNA levels were elevated following anti‐PD‐L1 treatment, consistent with activation‐linked checkpoint transcriptional responses under conditions of restored effector engagement (Figure 5f). Finally, we asked whether neutrophils modulate the in vivo growth defect caused by ACOT11 depletion. In xenograft experiments, ACOT11 knockdown significantly reduced tumor burden, while neutrophil supplementation partially rescued tumor growth, yielding higher endpoint tumor weights than the si‐ACOT11 group (Figure 5g). Together, these data support a working model in which ACOT11‐associated effects on tumor progression may involve neutrophil‐associated PD‐L1 checkpoint features that correlate with dampened T‐cell effector function (Figure 5a–g).

FIGURE 5.

FIGURE 5

ACOT11 engages a neutrophil–PD‐L1 correlation that suppresses T‐cell effector function and supports tumor growth. (a) Flow cytometry histograms (top) and quantification (bottom) of PD‐L1 mean fluorescence intensity (MFI) on LUAD cells under si‐NC, si‐ACOT11, and si‐ACOT11 + neutrophil conditions (IgG control shown in histogram). (b) PD‐L1 protein levels in neutrophils alone versus LUAD‐conditioned neutrophils (A549‐neutrophils and NCI‐H1975‐neutrophils), with representative immunoblot (bottom) and densitometric quantification (top). (c) A549 setting: TNF‐α, IFN‐γ, and perforin levels in co‐culture supernatants comparing CD8+ T cells + neutrophils treated with IgG versus anti‐PD‐L1. (d) NCI‐H1975 setting: TNF‐α, IFN‐γ, and perforin levels in co‐culture supernatants comparing IgG versus anti‐PD‐L1 conditions. (e) Representative Transwell images and quantification of migrated cells per field under neutrophils + IgG versus neutrophils + anti‐PD‐L1 conditions in A549 and NCI‐H1975 systems. (f) qRT–PCR analysis of PDCD1 (PD‐1) mRNA expression comparing neutrophils + IgG versus neutrophils + anti‐PD‐L1. Data (a–f) are presented as mean ± SD from n = 3 independent experiments. Comparisons between two groups were analyzed by unpaired Student's t‐test; comparisons among three or more groups were analyzed by one‐way ANOVA with Tukey's HSD post hoc test. (g) Xenograft endpoint tumors (left) and quantification of tumor weight (right) in si‐NC, si‐ACOT11, and si‐ACOT11 + neutrophil groups. Xenograft endpoint tumor weight was analyzed by one‐way ANOVA with Tukey's HSD post hoc test, n = 5 mice per group. Data are presented as mean ± SD.

4. Discussion

Our data support a model in which ACOT11 functions as a pathogenic integrator of lipid metabolism, oncogenic signaling, and tumor–immune crosstalk in NSCLC [4]. ACOT11 is elevated in lung cancer relative to normal tissue and associates with adverse clinical outcomes, consistent with previous work [4, 15]. Our functional results further show that ACOT11 suppression reduces tumor growth and attenuates proliferative and invasive phenotypes in A549 and NCI‐H1975 models.

ACOT11 modulation alters the FFA milieu [16, 17], which is consistent with its known biochemical function as a long‐chain fatty acyl‐CoA thioesterase [5, 18]. In our data, altering ACOT11 levels correspondingly shifts measured FFA abundance, suggesting that ACOT11 can increase the pool of free fatty acids available for receptor activation and downstream signaling within tumor cells. This is conceptually important because the tumor‐promoting consequences of ACOT11 are unlikely to be explained solely by “more fuel,” given that FFAs can initiate GPCR‐driven kinase cascades that directly control proliferation, apoptosis resistance, and motility [3, 19].

Experimentally, our rescue and inhibition experiments show that FFA supplementation restores growth, invasion, and metabolic outputs when ACOT11 is suppressed, and genetic disruption of GPR40 attenuates this rescue. These findings point to GPR40 as a contributing mediator in our models. Mechanistically, this observation is consistent with a “metabolite → receptor → kinase” logic, as FFAR1/GPR40 has been shown to engage Src and PI3K/AKT modules in other tumor systems [3, 19], and foundational work has established that FFAs can regulate cell physiology through GPCR pathways.

Experimentally, we observed that ACOT11 manipulation correlates with changes in AKT phosphorylation, and GPR40 knockdown reduced p‐AKT levels. Mechanistically, PI3K/AKT is a convergence point for GPCR and metabolic stress signaling [9, 20, 21], and its activation is repeatedly linked to chemoresistance in NSCLC [1, 7]. For example, PTEN stabilization and consequent PI3K/AKT inhibition increase cisplatin sensitivity, while pharmacologic PI3K interruption reverses gefitinib resistance [7, 8]. These precedents support our interpretation that ACOT11‐associated AKT activation (with PI3K involvement inferred from the p‐AKT data and prior reports) could contribute to chemoresistance.

Importantly, our study goes beyond signaling endpoints to demonstrate that ACOT11 materially remodels cellular energetics, as evidenced by coordinated changes in OCR/ECAR, ATP output, and lactate production. This phenotype is consistent with the concept that oncogenic signaling and metabolic flux are tightly coupled, where kinase cascades not only prevent apoptosis but also reprogram mitochondrial and glycolytic capacity to meet the energetic and biosynthetic demands of proliferating, therapy‐stressed cells [22]. A relevant parallel is provided by recent NSCLC work showing that altering a regulatory axis (ST14–TKT/OGT) reduces glycolytic flux and lactate production, with measurable consequences for tumor growth, underscoring that modulating metabolic pathways can be sufficient to constrain NSCLC proliferation [2]. In our data, ACOT11 suppression decreases metabolic performance measures that are typically associated with growth competence, while FFA supplementation restores these outputs in a receptor‐dependent manner, supporting a potential link from lipid hydrolysis to receptor signaling to energy metabolism.

The observation that ACOT11 influences both OCR and ECAR suggests that ACOT11 does not simply push cells toward “glycolysis only,” but instead increases overall metabolic throughput and flexibility. Such flexibility is increasingly recognized as a hallmark of drug‐tolerant cancer states, where cells maintain the ability to shift between oxidative and glycolytic programs depending on stress context, nutrient availability, and drug pressure [23, 24]. Our ATP and lactate measurements reinforce this interpretation because ATP abundance reflects net bioenergetic output, while lactate production indicates enhanced glycolytic or anaplerotic flux that can support redox balance and microenvironmental remodeling. The fact that these metabolic phenotypes are rescued by FFA but blocked when the FFA receptor node is disabled argues that ACOT11‐driven energetics are at least partly instructed by signaling rather than being a passive consequence of substrate supply.

A second major dimension of our findings is the observed association between ACOT11 and neutrophil‐associated tumor microenvironment features. We observe associations between ACOT11 expression and neutrophil infiltration metrics and validate increased neutrophil markers in tumor tissue, consistent with a scenario where ACOT11‐high tumors are embedded in a myeloid‐inflamed, immunosuppressive niche [25]. Mechanistically, our data identify altered expression of neutrophil‐relevant chemokine programs (including CXCL2) and inflammatory mediators (including SPP1/osteopontin), and these shifts track with ACOT11 perturbation and FFA/receptor dependency. This is biologically plausible because CXCR2 ligands such as CXCL2 are known to form gradients that drive recruitment of tumor‐associated neutrophils from the bone marrow to tumor tissue, enabling sustained TAN accumulation [10, 26].

Our functional assays extend beyond correlation by showing that manipulating ACOT11 affects migratory behavior in ways consistent with altered pro‐metastatic or pro‐invasion capacity, and that FFA supplementation restores migration when ACOT11 is suppressed in a receptor‐dependent manner. This matters for neutrophil biology because tumor‐derived cues that enhance invasion frequently overlap with chemokine programs that attract myeloid cells, creating a feed‐forward loop where invasion‐promoting tumors recruit TANs that further support tumor progression [27, 28]. While our study does not claim to resolve the full network, the consistency between chemokine changes, neutrophil marker evidence, and functional migration outputs strengthens the interpretation that ACOT11 contributes to a microenvironment‐permissive state.

A particularly actionable immune association highlighted by our data is PD‐L1 associated with neutrophils. Prior work in human hepatocellular carcinoma demonstrated that PD‐L1+ neutrophils suppress T‐cell proliferation and activation and that PD‐L1 blockade can partially reverse this suppression, establishing neutrophil PD‐L1 as a functional immune checkpoint mechanism rather than a passive marker [11]. Similarly, in gastric cancer, tumor‐activated neutrophils have been shown to express PD‐L1 via tumor‐derived factors and to promote immune suppression and disease progression, with PD‐L1 blockade reversing neutrophil‐mediated suppression in vivo [29]. These results were consistent with our study.

Our anti‐PD‐L1 intervention experiments further support causality by showing that blocking PD‐L1 in neutrophil–tumor cell interaction settings modulates inflammatory and/or growth‐associated outputs. This is consistent with the broader literature demonstrating that PD‐L1 is not restricted to tumor cells and can be induced on myeloid populations under inflammatory cues, including neutrophils, with meaningful immunosuppressive consequences [30]. Although much of the clinical checkpoint biomarker focus in lung cancer has been on tumor‐cell PD‐L1, clinical datasets also emphasize that PD‐L1 biology interfaces with systemic inflammatory status (e.g., neutrophil‐to‐lymphocyte ratio), consistent with immune context shaping outcomes. Thus, our findings support a working model in which ACOT11‐associated lipid signaling may contribute to both cancer‐cell survival signaling and metabolic output, and may also be associated with a TAN/PD‐L1 immunosuppressive module that could influence antitumor immunity during therapy.

There are important boundaries to interpretation. First, FFA receptors can have context‐dependent roles across tumor types, and prior work in non‐lung systems shows that FFAR1/GPR40 activation can differentially affect migration versus proliferation depending on downstream pathway bias and cell context, emphasizing that receptor coupling is not uniform [3]. Second, while our neutrophil data support functional involvement, TAN phenotypes are heterogeneous, and PD‐L1 is only one axis among many by which neutrophils shape tumor immunity [31, 32], so additional profiling would be required to map the full TAN state space in ACOT11‐high tumors. Third, although AKT emerges as a key, experimentally supported node—consistent with upstream PI3K involvement—resistant states often involve parallel pathways and feedback loops, and our results should be interpreted as defining a dominant, experimentally supported route rather than excluding other resistance mechanisms.

Despite these caveats, our findings suggest several potential therapeutic angles. Targeting ACOT11 could reduce FFA availability and blunt receptor signaling and metabolic support. Disrupting GPR40 could decouple lipid signals from downstream AKT signaling. Additionally, combining metabolic/receptor interventions with PD‐L1 blockade may be attractive in tumors where PD‐L1+ neutrophils contribute to immune suppression.

Overall, our findings suggest a working model (Figure 6) in which ACOT11 may coordinate lipid‐derived signaling, AKT‐related drug tolerance (consistent with PI3K/AKT pathway engagement), metabolic amplification, and neutrophil/PD‐L1‐associated immunomodulation. Experimentally, ACOT11 suppression reduces tumor growth, attenuates proliferative/invasive phenotypes, decreases OCR/ECAR and ATP/lactate outputs, and correlates with reduced SPP1/CXCL2 expression. Mechanistically, these phenotypes are reinforced by an FFA–GPR40 correlation that activates AKT signaling and elevates energetic capacity, while ACOT11 also aligns with neutrophil‐associated inflammation programs and a PD‐L1‐associated myeloid module. This model provides a biologically plausible explanation for associations between ACOT11 expression and poor outcomes, and suggests that ACOT11‐centered interventions could simultaneously weaken tumor‐cell intrinsic resistance and relieve immune suppression.

FIGURE 6.

FIGURE 6

Proposed mechanism depicting ACOT11 as an integrator of lipid metabolism, signaling, and immune evasion in NSCLC. Within the NSCLC tumor cell, ACOT11 thioesterase activity hydrolyzes Acyl‐CoA, increasing the intracellular pool of bioactive free fatty acids (FFAs). These FFAs serve as ligands for the G‐protein–coupled receptor GPR40 (FFAR1), consistent with activation of the PI3K/AKT signaling cascade (proposed mechanism). Downstream phosphorylated AKT (p‐AKT) coordinates multiple pro‐tumorigenic outputs: (1) promotion of proliferation, migration, and survival programs; (2) metabolic reprogramming characterized by increased mitochondrial respiration (OCR), glycolytic flux (ECAR), and energetic output (ATP and lactate); and (3) induction of inflammatory chemokine and cytokine expression (e.g., CXCL2, SPP1). Secreted CXCL2 drives the recruitment of tumor‐associated neutrophils (TANs) into the tumor microenvironment (TME). These recruited TANs express PD‐L1, which engages PD‐1 on cytotoxic T‐cells, thereby suppressing T‐cell effector functions (inhibiting production of IFN‐γ, TNF‐α, and perforin) and reducing T‐cell infiltration. This figure depicts a proposed working model: the convergence of these tumor‐intrinsic metabolic/signaling features and microenvironmental immune‐associated features may contribute to tumor growth and chemoresistance. However, the complete ACOT11–GPR40–neutrophil–PD‐L1 sequence has not been directly demonstrated as a single causal pathway and should be interpreted as a hypothesis‐generating framework.

This study has several limitations. First, although the association between ACOT11 expression and neutrophil‐related features, together with increased MPO staining, suggests a role in microenvironmental regulation, the causal relationship between ACOT11 and neutrophil recruitment in vivo remains to be established through functional blockade experiments. Second, whether ACOT11 directly regulates PD‐L1 expression in tumor cells or exerts its effects indirectly through neutrophil‐mediated mechanisms has not been clearly delineated. Thus, the proposed ACOT11–GPR40–neutrophil–PD‐L1 sequence should be interpreted as a working model or hypothesis‐generating framework rather than an established causal pathway. Third, while our in vivo experiments confirm that ACOT11 knockdown suppresses tumor growth and that neutrophil supplementation partially rescues this effect, the GPR40 signaling pathway and PD‐L1‐dependent immune mechanisms have not been functionally validated in vivo. Collectively, these limitations underscore the need for further mechanistic investigation to consolidate the proposed model.

5. Conclusion

Our findings suggest that ACOT11 may correlate with the progression of lung cancer by amplifying a stress‐adaptive state characterized by increased FFA availability, engagement of an FFA receptor (GPR40/FFAR1 in our models), AKT signaling (consistent with PI3K/AKT pathway engagement), and enhanced bioenergetic and biosynthetic capacity. In parallel, ACOT11 is associated with the function of neutrophils and PD‐L1. ACOT11 might be a potential target and prognosis biomarker for lung cancer.

Funding

This work was supported by the project of the China Association for Promotion of Health Science and Technology (Grant No. JKHY2023003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics Statement

This study was approved by the Peking University Third Hospital Medical Science Research Ethics Committee (2025‐472‐01). The study was conducted according to the guidelines of the Declaration of Helsinki. All participants have signed the informed consents.

This work has obtained the approval of the Peking University Third Hospital Experimental Animal Ethics Committee (2025‐115‐02). All the operations followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and ARRIVE Guidelines pertaining to animal experimentation.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  • 1. Fu J., Xu W., Wang G., et al., “Hypoxia‐Triggered Autophagy Modulates Cisplatin Resistance in Non‐Small Cell Lung Cancer via EIF2AK3‐Dependent PI3K/AKT Signaling and mTOR‐Independent Mechanisms,” Cell Death Discovery 12 (2025): 40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Ji L., Zhang M., Liu Y., et al., “Suppressor of Tumorigenicity 14 Inhibits Non‐Small Cell Lung Cancer Cell Proliferation by Suppressing Transketolase O‐GlcNAcylation,” Experimental Cell Research 452 (2025): 114776, 10.1016/j.yexcr.2025.114776. [DOI] [PubMed] [Google Scholar]
  • 3. Karmokar P. F. and Moniri N. H., “Free‐Fatty Acid Receptor‐1 (FFA1/GPR40) Promotes Papillary RCC Proliferation and Tumor Growth via Src/PI3K/AKT/NF‐κB but Suppresses Migration by Inhibition of EGFR, ERK1/2, STAT3 and EMT,” Cancer Cell International 23 (2023): 126, 10.1186/s12935-023-02967-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Liang C., Wang X., Zhang Z., et al., “ACOT11 Promotes Cell Proliferation, Migration and Invasion in Lung Adenocarcinoma,” Translational Lung Cancer Research 9 (2020): 1885–1903, 10.21037/tlcr-19-509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Zhang Y., Li Y., Niepel M. W., et al., “Targeted Deletion of Thioesterase Superfamily Member 1 Promotes Energy Expenditure and Protects Against Obesity and Insulin Resistance,” Proceedings of the National Academy of Sciences of the United States of America 109 (2012): 5417–5422, 10.1073/pnas.1116011109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Hirasawa A., Tsumaya K., Awaji T., et al., “Free Fatty Acids Regulate Gut Incretin Glucagon‐Like Peptide‐1 Secretion Through GPR120,” Nature Medicine 11 (2005): 90–94, 10.1038/nm1168. [DOI] [PubMed] [Google Scholar]
  • 7. Xu M., Deng X., Xiang N., Zhang Z., Yang M., and Liu Q., “Plk3 Enhances Cisplatin Sensitivity of Nonsmall‐Cell Lung Cancer Cells Through Inhibition of the PI3K/AKT Pathway via Stabilizing PTEN,” ACS Omega 9 (2024): 8995–9002, 10.1021/acsomega.3c07271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Yu Y., Xiao Z., Lei C., et al., “BYL719 Reverses Gefitinib‐Resistance Induced by PI3K/AKT Activation in Non‐Small Cell Lung Cancer Cells,” BMC Cancer 23 (2023): 732, 10.1186/s12885-023-11243-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Liu H., Zhu Y., Niu H., et al., “Activation of PI3K/Akt Pathway by G Protein‐Coupled Receptor 37 Promotes Resistance to Cisplatin‐Induced Apoptosis in Non‐Small Cell Lung Cancer,” Cancer Medicine 12 (2023): 19777–19793, 10.1002/cam4.6543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Jablonska J., Wu C. F., Andzinski L., Leschner S., and Weiss S., “CXCR2‐Mediated Tumor‐Associated Neutrophil Recruitment Is Regulated by IFN‐β,” International Journal of Cancer 134 (2014): 1346–1358, 10.1002/ijc.28551. [DOI] [PubMed] [Google Scholar]
  • 11. He G., Zhang H., Zhou J., et al., “Peritumoural Neutrophils Negatively Regulate Adaptive Immunity via the PD‐L1/PD‐1 Signalling Pathway in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 34 (2015): 141, 10.1186/s13046-015-0256-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Vandesompele J., De Preter K., Pattyn F., et al., “Accurate Normalization of Real‐Time Quantitative RT‐PCR Data by Geometric Averaging of Multiple Internal Control Genes,” Genome Biology 3 (2002): Research0034, 10.1186/gb-2002-3-7-research0034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Sankoda A., Harada N., Kato T., et al., “Free Fatty Acid Receptors, G Protein‐Coupled Receptor 120 and G Protein‐Coupled Receptor 40, Are Essential for Oil‐Induced Gastric Inhibitory Polypeptide Secretion,” Journal of Diabetes Investigation 10 (2019): 1430–1437, 10.1111/jdi.13059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Suckow A. T., Polidori D., Yan W., et al., “Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice: A Role for GPR120 in Glucagon Secretion,” Journal of Biological Chemistry 289 (2014): 15751–15763, 10.1074/jbc.M114.568683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Hung J. Y., Chiang S. R., Liu K. T., et al., “Overexpression and Proliferation Dependence of Acyl‐CoA Thioesterase 11 and 13 in Lung Adenocarcinoma,” Oncology Letters 14 (2017): 3647–3656, 10.3892/ol.2017.6594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Al Mahri S., Malik S. S., Al Ibrahim M., Haji E., Dairi G., and Mohammad S., “Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook,” Cells 11 (2022): 750, 10.3390/cells11040750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Pardella E., Ippolito L., Giannoni E., and Chiarugi P., “Nutritional and Metabolic Signalling Through GPCRs,” FEBS Letters 596 (2022): 2364–2381, 10.1002/1873-3468.14441. [DOI] [PubMed] [Google Scholar]
  • 18. Han S. and Cohen D. E., “Functional Characterization of Thioesterase Superfamily Member 1/Acyl‐CoA Thioesterase 11: Implications for Metabolic Regulation,” Journal of Lipid Research 53 (2012): 2620–2631, 10.1194/jlr.M029538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Matoba A., Matsuyama N., Shibata S., Masaki E., C. W. Emala, Sr. , and Mizuta K., “The Free Fatty Acid Receptor 1 Promotes Airway Smooth Muscle Cell Proliferation Through MEK/ERK and PI3K/Akt Signaling Pathways,” American Journal of Physiology. Lung Cellular and Molecular Physiology 314 (2018): L333–L348, 10.1152/ajplung.00129.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Khalil B. D., Hsueh C., Cao Y., et al., “GPCR Signaling Mediates Tumor Metastasis via PI3Kβ,” Cancer Research 76 (2016): 2944–2953, 10.1158/0008-5472.CAN-15-1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Leroy C., Ramos P., Cornille K., et al., “Activation of IGF1R/p110β/AKT/mTOR Confers Resistance to α‐Specific PI3K Inhibition,” Breast Cancer Research 18 (2016): 41, 10.1186/s13058-016-0697-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Hoxhaj G. and Manning B. D., “The PI3K‐AKT Network at the Interface of Oncogenic Signalling and Cancer Metabolism,” Nature Reviews. Cancer 20 (2020): 74–88, 10.1038/s41568-019-0216-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Addissouky T. A., “Metabolic Reprogramming in Non‐Small Cell Lung Cancer: Unraveling Therapeutic Vulnerabilities and Resistance Mechanisms,” Journal of Rare Diseases 5 (2026): 4, 10.1007/s44162-026-00147-9. [DOI] [Google Scholar]
  • 24. Khan T., Nagarajan M., Kang I., Wu C., and Wangpaichitr M., “Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy,” Journal of Personalized Medicine 15 (2025): 50, 10.3390/jpm15020050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Huang X., Nepovimova E., Adam V., et al., “Neutrophils in Cancer Immunotherapy: Friends or Foes?,” Molecular Cancer 23 (2024): 107, 10.1186/s12943-024-02004-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. McFarlane A. J., Fercoq F., Coffelt S. B., and Carlin L. M., “Neutrophil Dynamics in the Tumor Microenvironment,” Journal of Clinical Investigation 131 (2021): e143759, 10.1172/JCI143759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Chen E. and Yu J., “The Role and Metabolic Adaptations of Neutrophils in Premetastatic Niches,” Biomarker Research 11 (2023): 50, 10.1186/s40364-023-00493-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Long W., Chen J., Gao C., Lin Z., Xie X., and Dai H., “Brief Review on the Roles of Neutrophils in Cancer Development,” Journal of Leukocyte Biology 109 (2021): 407–413, 10.1002/JLB.4MR0820-011R. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Wang T. T., Zhao Y. L., Peng L. S., et al., “Tumour‐Activated Neutrophils in Gastric Cancer Foster Immune Suppression and Disease Progression Through GM‐CSF‐PD‐L1 Pathway,” Gut 66 (2017): 1900–1911, 10.1136/gutjnl-2016-313075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Tang D., Zhang D., Heng Y., et al., “Tumor‐Infiltrating PD‐L1+ Neutrophils Induced by GM‐CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis,” Journal of Inflammation Research 15 (2022): 1079–1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Yao J., Ji L., Wang G., and Ding J., “Effect of Neutrophils on Tumor Immunity and Immunotherapy Resistance With Underlying Mechanisms,” Cancer Commun (Lond) 45 (2025): 15–42, 10.1002/cac2.12613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Du Q., An Q., Zhang J., Liu C., and Hu Q., “Unravelling Immune Microenvironment Features Underlying Tumor Progression in the Single‐Cell Era,” Cancer Cell International 24 (2024): 143, 10.1186/s12935-024-03335-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from Iubmb Life are provided here courtesy of Wiley

RESOURCES